Latest Breaking News On - Novo nordisk glucagen - Page 1 : comparemela.com

Posted on 7691 Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation is valid in all 27 countries of the European Union, plus Iceland, Norway, and Liechtenstein. As the EC decision was received after the end of the Brexit transition period, Xeris will complete a further administrative step in order to obtain a license in Great Britain. No re-examination of clinical data by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) is expected.

United statesUnited kingdomGreat britainThomas pieberAllison weyGvoke hypopenNovo nordisk glucagenPaulr edickXeris pharmaceuticalsDivision of endocrinologyAmerican diabetes associationEuropean unionPyramid laboratories incCommittee for medicinal products human useXeris pharmaceuticals incDepartment of internal medicine